Bondrova 150 mg (Tablet)
1 tablet kit: ৳ 1,960.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Ibandronic acid |
| Company | Healthcare pharmaceuticals ltd |
| Also available as |
Indications
- Treatment of osteoporosis in women (specially postmenopausal)
- Prevention of osteoporosis in women (specially postmenopausal)
- Prevention and treatment of osteoporosis in men
Pharmacology
- Inhibition of bone resorption
- Prevention of experimentally induced bone destruction
- Highly potent inhibitor of osteoclastic activity
Dosage & Administration
- Recommended dose of one 150 mg film-coated tablet once a month
- Tablet to be taken 60 minutes before the first food or drink
- Tablet to be swallowed whole with plain water
Interaction
- Interference with the absorption of calcium supplements and antacids
- No interaction potential with tamoxifen or hormone replacement therapy
- Increase in bioavailability with i.v. ranitidine
Contraindications
- Known hypersensitivity to ibandronic acid or excipients
- Uncorrected hypocalcemia
- Abnormalities of the esophagus delaying esophageal emptying
Side Effects
- Dyspepsia
- Nausea
- Diarrhea
Pregnancy & Lactation
- Not to be used during pregnancy
- No clinical experience in pregnant women
- Not to be used during lactation
Precautions & Warnings
- Treat hypocalcemia before starting therapy
- Caution in patients with active upper gastrointestinal problems
- Alert for signs of possible esophageal reactions
Use in Special Populations
- No dosage adjustment for patients with mild or moderate renal impairment
- No dosage adjustment for patients with hepatic impairment
- No dosage adjustment for elderly patients
Overdose Effects
- Oral overdosage may result in upper gastrointestinal adverse events
- Milk or antacids should be given to bind Bondrova
Therapeutic Class
- Bisphosphonate preparations
Storage Conditions
- Keep below 30°C temperature, away from light & moisture